Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q6ZRP7

UPID:
QSOX2_HUMAN

ALTERNATIVE NAMES:
Neuroblastoma-derived sulfhydryl oxidase; Quiescin Q6-like protein 1

ALTERNATIVE UPACC:
Q6ZRP7; A2CEE0; A6NLB0; Q5TB37; Q7Z7B6; Q86VV7; Q8N3G2

BACKGROUND:
The enzyme Sulfhydryl oxidase 2, recognized by its alternative names Neuroblastoma-derived sulfhydryl oxidase and Quiescin Q6-like protein 1, catalyzes the critical step of converting peptide and protein thiols into disulfides. This action is vital for the proper folding and stability of secretory proteins, indicating its significant role in cellular function.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Sulfhydryl oxidase 2 offers a promising pathway to novel therapeutic approaches. Its key role in the regulation of protein secretion and stability highlights its potential as a target in diseases where these processes are disrupted.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.